Bristol-Myers Squibb Canada Co. announced last Friday the company reached an agreement with the pan-Canadian Pharmaceutical Alliance for the immuno-oncology treatment Opdivo, or nivolumab, bringing patients with advanced, difficult-to-treat cancers closer to accessing a new treatment option.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
